U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06910657) titled 'Phase I Study of IDOV-Immune to Evaluate Safety and Antitumor Activity in Adults With Advanced Solid Tumors' on March 21.
Brief Summary: This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor.
The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely g...